北大医药(000788.SZ)：拟通过公开竞拍方式购买西南合成所持大新药业9.75%股份

Core Viewpoint - The company aims to reduce operational uncertainties related to its reliance on the leasing of production assets from Daxin Pharmaceutical by strategically investing in the raw material pharmaceutical industry, thereby enhancing the stability and continuity of its production system [1] Group 1: Strategic Investment - The company plans to use its own funds to publicly bid for a 9.75% stake in Daxin Pharmaceutical held by Southwest Synthesis, with the transaction price based on an asset evaluation report [2] - The estimated value of Daxin Pharmaceutical's total equity is 232.5 million yuan, with the assessed value of the 9.75% stake being approximately 22.6688 million yuan [2] Group 2: Industry Collaboration - By deepening collaboration within the upstream supply chain, the company expects to directly benefit from the potential profit increases associated with the positive development trends in the raw material pharmaceutical industry [1] - This strategic move is anticipated to optimize the company's overall profitability and achieve a win-win situation within the industry chain [1]